Cardiovascular Risk and MASLD – Integrating Lipid Management with Novel Agents
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on X:
“Understanding MASLD, from molecular pathogenesis to cardiovascular risk.
A concise review for the clinical cardiologist.
MASLD not only drives liver injury but also worsens lipid metabolism, fueling atherogenic dyslipidemia. Increased VLDL, small dense LDL, dysfunctional HDL.
The review in ATH journal highlights that.
•Statins are both safe and effective in MASLD, yet underprescribed.
•Ezetimibe and pemafibrate may improve lipid profile and hepatic parameters.
•GLP-1RAs and SGLT2i show dual benefit on liver fat, cardiometabolic risk, and CVD outcomes.
•Emerging agents (resmetirom, lanifibranor) target both hepatic fibrosis and lipid metabolism.
Lipid-lowering therapy remains central in MASLD management, but must be integrated with newer agents for optimal cardio-hepatic protection .”
Read more here.
Stay informed with Hemostasis Today.
-
Oct 9, 2026, 16:23David Boone: Distinguishing Stroke Prevention from Rhythm Control in Atrial Fibrillation
-
Oct 9, 2026, 15:27Mohamed Hegazi: Geostatistical Modelling Maps Global β-Thalassaemia Carrier Prevalence
-
Oct 9, 2026, 15:15Maha Othman: Uncovering the Consensus on TXA in TBI – Call for Collaboration on a Landmark Umbrella Review
-
Oct 9, 2026, 15:07Daniel D. Han: How Inhalation Product Exposure Impairs Cardiac and Platelet Recovery After MI
-
Oct 9, 2026, 14:58William Toole: How Ultrasound-Guided PRP Therapy Relieves Joint and Tendon Pain
-
Oct 9, 2026, 14:50Shayan Mohammadmoradi: In Corpus Christi for the 20th Midwest Platelet Conference
-
Oct 9, 2026, 14:37Tariq Tramboo: High Platelet Concentrate for Osteoarthritis Knee – Recent Meta-Analyses
-
Oct 9, 2026, 14:26Yousma Khan: Hematology Series – Beyond RBCs, WBCs and Platelets
-
Oct 9, 2026, 14:13Jesus Ardila Novoa: Why the WHO’s Historic Essential Medicines List Decision Is Just the Beginning